Scientific Publication
Protease-activated anti-Lewis Y antibody enhances selectivity and safety of glycan-targeting cancer therapy
Read MoreProtease-activated anti-Lewis Y antibody enhances selectivity and safety of glycan-targeting cancer therapy
GlycoNex and PrecisemAb Co-Develop an Innovative Pro-Antibody Demonstrating High Tumor Selectivity and Safety; Research Published in an International Journal
PrecisemAb Biotech Co., Ltd. extends its sincere congratulations to the team at GlycoNex Inc.! We are…
PrecisemAb Biotech Unveils an Innovative Antibody Lock Mechanism to Overcome Anti-Idiotypic Antibody Interference in Long-Term Antibody Therapies
We are excited to announce our second publication of the year.The study titled “Spatial-hindrance-based pro-Adalimumab prevents…
PrecisemAb Publishes New Research on Tumor-Selective Activation Antibodies in the International Journal of Biological Macromolecules
We are pleased to share that our latest research article,“Development of a tumor-region-selective activation monoclonal antibody…
